CanariaBio is a biotechnology company focused on the development of innovative cancer therapies, specifically targeting ovarian cancer, pancreatic cancer, and metastatic breast cancer. The company is advancing a pipeline of drug candidates, with a particular emphasis on a monoclonal antibody called Oregovomab, which is being evaluated in various clinical trial phases. These trials include combinations of Oregovomab with chemotherapy and other agents, such as Niraparib and Bevacizumab, to enhance treatment efficacy for recurrent ovarian cancer. The company is also exploring the use of Brevarek in conjunction with chemotherapy for pancreatic cancer, indicating a robust commitment to addressing multiple cancer types through targeted therapies.

The R&D pipeline of CanariaBio showcases a strategic approach to drug development, with ongoing clinical trials at different stages, including Phase 1, Phase 2, and Phase 3. The combination therapies being investigated aim to improve patient outcomes by leveraging the synergistic effects of Oregovomab with established chemotherapeutic agents. This innovative approach reflects the company's dedication to advancing cancer treatment options and highlights its role in the biopharmaceutical landscape, where the focus is on developing effective therapies for challenging malignancies.

South Korea

CanariaBio is a biopharmaceutical company that focuses on developing and commercializing immunotherapies for cancer, utilizing a technology platform of tumor antigen specific monoclonal immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu.

CanariaBio

Company Details